Milind Parikh, DO
Cardiovascular Disease · Chula Vista, CANPI 1194161406
Payments from drug & device makers
Across 472 payments — averaging $3302.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cleerly, Inc.$1.5M
- AstraZeneca$18K
- Abbott$8K
- Heartflow, Inc.$5K
- Biotronik Inc.$2K
- Boston Scientific$2K
- plus $8K from 28 others
What the payments were for
- Consulting fees$5,67522%
- Travel & lodging$2,56110%
- Food & beverage$16,83066%
- Education$2551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cleerly, Inc. | 33 | $1,515,826 |
| AstraZeneca | 7 | $17,706 |
| Abbott | 145 | $7,739 |
| Heartflow, Inc. | 26 | $5,397 |
| Biotronik Inc. | 4 | $2,268 |
| Boston Scientific | 47 | $2,066 |
| Edwards Lifesciences | 18 | $1,925 |
| Medtronic(2 entities) | 22 | $866 |
| Johnson & Johnson | 38 | $724 |
| Shockwave Medical, Inc | 4 | $579 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 23 | $559 |
| AOP Health US, LLC | 1 | $497 |
| Novartis | 25 | $439 |
| Amgen | 19 | $387 |
| Astellas Pharma US Inc | 8 | $324 |
| Impulse Dynamics (USA) Inc. | 2 | $251 |
| Pfizer | 13 | $224 |
| Merck | 8 | $199 |
| Biosense Webster, Inc. | 2 | $114 |
| Acera Surgical, Inc. | 1 | $107 |
| Novo Nordisk | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $78 |
| Abiomed | 2 | $67 |
| Cvrx, Inc. | 2 | $50 |
| Canon Medical Systems USA, Inc. | 1 | $41 |
| Atricure, Inc. | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $32 |
| Reflow Medical Inc | 2 | $30 |
| Boehringer Ingelheim | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Cardiva Medical, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$4,902
- MitraClip$1,582
- Rapiblyk$995
- SAPIEN 3 Ultra RESILIA$901
- Confirm Rx$568
- OPTIMIZER$503
- Watchman$477
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$454
- Mitra Clip system$444
- AVEIR$404
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$380
- Quadra Assura CRT Defibrillator$284
- WATCHMAN Access System$260
- GENERAL - THERAPIES$223
- Micra$220
- EVERA MRI XT DR SURESCAN$200
- ENSITE$170
- JOT DX$165
- Farapulse$150
- VersaCross Access Solution$148
How this compares
$1,558,748 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $36,268 |
| XareltoRivaroxaban | 27 | $34,925 |
| EntrestoSacubitril/Valsartan | 22 | $26,859 |
| BrilintaTicagrelor | 11 | $12,529 |
| VascepaIcosapent Ethyl | 11 | $4,449 |
| Rosuvastatin Calcium | 55 | $1,746 |
| Ranolazine ErRanolazine | 19 | $1,154 |
| Metoprolol Succinate | 81 | $1,138 |
| Amlodipine Besylate | 111 | $452 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 34 | $445 |
| Chlorthalidone | 34 | $401 |
| Atorvastatin Calcium | 48 | $350 |
| Losartan Potassium | 43 | $273 |
| Lisinopril | 35 | $157 |
| Carvedilol | 45 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $224 | $36,26836 claims |
| Johnson & JohnsonXarelto | $724 | $34,92527 claims |
| NovartisEntresto | $439 | $26,85922 claims |
| AstraZenecaBrilinta | $17,706 | $12,52911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Chula Vista
- Brett BermanChula Vista$1.7M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.